Mycoxolamine 1% cream 30g

NAME
MICOXOLAMINE

PHARMACOTHERAPEUTIC CATEGORY
Topical antifungals.

ACTIVE PRINCIPLES
Cyclopyroxolamine.

EXCIPIENTS
Cream: ethylene glycol and polyoxyethylene glycol palmito-stearic acids, polyoxyethylene saturated fatty acids glyceridides, petroleum jelly, benzoic acid, butylhydroxyanisole, purified water. Skin emulsion: ethylene glycol and polyoxyethylene glycol palmito-stearic, glycerides of polyoxyethylene saturated fatty acids, petroleum jelly, benzoic acid, lactic acid, butylhydroxyanisole, purified water. Skin solution: monoethanolamine lauryl sulfate, polyethylene glycol 150 stearate, polysorbate 20, lecithindiethanolamide, sodium edetate, benzyl alcohol, perfume, lactic acid, purified water.

INDICATIONS
Skin mycoses sustained by sensitive fungi.

CONTRAINDICATIONS / SECONDARY EFFECT
Hypersensitivity 'to the active substance or to any of the excipients.

DOSAGE
The different preparations allow to adopt, in the opinion of the doctor, the one most suitable for the individual case. Unless otherwise prescribed, the dosage is usually the following. Skin cream and emulsion: the cream is particularly suitable for hairless surfaces and limited extensions. Apply 2 or 3 times a day, depending on the severity of the disease, on the lesions and immediately surrounding areas, with a light massage. Repeat the treatment until the lesions disappear (usually 1-2 weeks). To prevent relapses, it is advisable to continue the therapy for a further 1-2 weeks. An occlusive dressing is recommended in the treatment of onychomycosis. Cutaneous solution: the cutaneous solution is particularly suitable for the treatment and prevention of pityriasis versicolor, as well as sensitive infections of the scalp, such as those caused by Malassetia sp., Seborrheic dermatitis and pityriasis capitis (dandruff). Apply the solution on the areas affected by the infection with a light massage; leave the product to act for about 3-5 minutes before rinsing. In pityriasis versicolor it is recommended to perform the treatment 1 to 3 times a day until the lesions disappear, usually for 1-2 weeks. In pityriasis capitis (dandruff) and seborrheic dermatitis of the scalp perform 2-3 treatments per week for 2-4 weeks. In the opinion of the doctor, treatment with the cutaneous solution can be continued for a further 1-2 weeks in order to reduce the risk of relapse.

STORAGE
1% cream: none. 1% skin emulsion: none. 1% cutaneous solution: store at a temperature not exceeding 25 degrees C.

WARNINGS
The product should not be used in ophthalmic diseases. Cyclopyroxolamine should be used with caution: in case of concomitant systemic antifungal treatment; in subjects with a history of immunosuppression; in patients with compromised immune systems, such as transplant recipients and those with HIV infection; in diabetic subjects. The use, especially if prolonged, of drugs for topical use can give rise to sensitization phenomena. In this case it is necessary to suspend the treatment and institute suitable therapeutic measures. In the course of treatment, hygiene measures must be strictly observed.

INTERACTIONS
They are not known.

SIDE EFFECTS
Occasionally, itching and burning or skin irritation, usually transient, may occur.

PREGNANCY AND BREASTFEEDING
In pregnant women, during lactation and in very early childhood, the medicine should be used only in cases of real need '.